Stay Alert for Situations Where Viberzi Should Be Avoided

FDA is now warning to avoid the irritable bowel syndrome med, Viberzi (eluxadoline), in patients who don't have a gallbladder.

This is due to an increased risk of serious pancreatitis that can result in hospitalization or death in these patients.

Viberzi may cause digestive juices to back up into the pancreas. Patients without gallbladders can't store the excess fluid...and can end up with an inflamed pancreas.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote